The IMID Forum

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2026 (Tuesday 10th November)

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2026 (Monday 9th November)

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2026 (Sunday 8th November)

Join Doctor Sofia Ramiro and Professor Phillip Mease as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2026

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Ibis et al. and Russell et al. which explore how targeted therapies may improve outcomes in patients with RA.

Join Professor Peter Nash from Griffith University in Brisbane and Doctor Mark Gibson from the Centre for Rheumatic Diseases, King’s College London, as they discuss Doctor Gibson’s recent paper, ‘Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs’.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Laura Coates and Professor Philip Mease as they discuss recent publications that explored treatment-refractory PsA through real-world EULAR-informed definitions and the longitudinal effects of zasocitinib on TYK2 signalling, inflammation, skin and joint disease, tissue turnover, and clinical response.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review paper by Bechman et al. where he highlights the impact of BMI on response to JAK inhibitors in RA.